Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2018: 156.09

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 8, Issue 3

Issues

Volume 10 (2015)

Urine saturation and promoter/inhibitor parameters and ratios in renal stone disease caused by ceftriaxone

Danko Milošević
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Branko Miše / Ivan Habuš / Marija Topalović-Grković / Danica Batinić
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Anja Golubić
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Daniel Turudić
  • Department for Pediatric Nephrology, University Children’s Hospital Zagreb, Zagreb School of Medicine, Kišpatićeva 12, 10000, Zagreb, Croatia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2013-04-17 | DOI: https://doi.org/10.2478/s11536-012-0091-z

Abstract

During ceftriaxone treatment of subdural empyema caused by Streptococcus intermedius urinary and biliary stones were noticed. Increased levels of urinary calcium excretion were detected during ongoing treatment in comparison with 2 months check-up. There were no significant changes in the promoter/inhibitor urolithiasis parameters, oxalate, citrate, urate, cistine, glycosaminoglycans or their ratios. Urine saturation was calculated using EQUIL 2 computer programme (calcium oxalate, brushite) and it was normal. Probable trigger for the ceftriaxone/calcium hydroxy carbonate phosphate mixture of stones was a critical boost of solubility products caused by ceftriaxone treatment and phospnate urine content with a subsequent large-scale spontaneous precipitation of crystals.

Keywords: Ceftriaxone; Urolythiasis; Urine saturation; Stone promoters/inhibitors

  • [1] Schaad UB., Wedgwood-Krucko J., Tschaeppler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet, 1988, 8625, 1411–1413 http://dx.doi.org/10.1016/S0140-6736(88)90596-XCrossrefGoogle Scholar

  • [2] de Moor RA., Egberts AC., Schröder CH. Ceftriaxone associated nephrolythiasis and biliary pseudolithiasis. EUR J Pediatr, 1999, 158, 975–977 http://dx.doi.org/10.1007/s004310051261CrossrefGoogle Scholar

  • [3] Bor O., Dinleyici EC., Kebapci M., Aydogdu SD. Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int, 2004, 46, 322–324 http://dx.doi.org/10.1111/j.1328-0867.2004.01884.xCrossrefGoogle Scholar

  • [4] Acun C., Erdem LO., Söğüt A., Erdem CZ., Tomaç N., Gündoğdu S., et al. Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study., Ann Trop Pediatr, 2004, 24, 25–31 http://dx.doi.org/10.1179/027249304225013349CrossrefGoogle Scholar

  • [5] Gargollo PC., Barnewolt CE., Diamond DA. Pediatric ceftriaxone nephrolythiasis. J Urol, 2005, 173, 577–578 http://dx.doi.org/10.1097/01.ju.0000148801.12464.b3CrossrefGoogle Scholar

  • [6] Mohkam M., Karimi A., Gharib A., Daneshmand H., Khatami A., Ghojevand N., et al. Ceftriaxone associated nephrolythiasis: a prospective study in 284 children. Pediatr nephrol, 2007, 22, 690–694 http://dx.doi.org/10.1007/s00467-006-0401-2Web of ScienceGoogle Scholar

  • [7] Avci Z., Koktener A., Uras N., Catal F., Karadag A., Tekin O., et al. Nephrolythiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child, 2004, 89, 1069–1072 http://dx.doi.org/10.1136/adc.2003.044156CrossrefGoogle Scholar

  • [8] Karlizcek SB., Döring S., Vogt S., et al.Ceftriaxone-associated nephrolythiais. Two case reports. Monatsschr Kinderheilkd, 1996, 144, 702–706 Google Scholar

  • [9] Kimata T., Kaneko K., Takahashi M., Hirabayashi M., Shimo T., Kino M. Increased urinary calcium excretion caused by ceftriaxone: possible association with urolythiasis. Pediatr nephrol, 2012, 27, 605–609 http://dx.doi.org/10.1007/s00467-011-2038-zCrossrefWeb of ScienceGoogle Scholar

  • [10] Lozanovski VJ., Gucev Z., Avramoski VJ., Kirovski I., Makreski P., Tasic V. Ceftriaxone associated urolithisis in a child with hypercalciuria. Hippokratia, 2011, Apr–Jun 15(2),181–183 Google Scholar

  • [11] Milošević D., Batinić D. Blau N., Konjevoda P., Štambuk N., Votava-Raić A., et al.Determination of urine saturation with computer program Equil 2 as a method for estimation of the risk of urolithiasis. J Chem Inf Comput Sci, 1998, 38(4), 646–650 http://dx.doi.org/10.1021/ci9701087CrossrefGoogle Scholar

  • [12] Batinić D., Milošević D., Blau N., Konjevoda P., Štambuk N., Barbarić V., et al. of the stone promoters/inhibitors ratios in the estimation of the risk of urolithiasis. J Chem Comput Sci, 2000, 40(3), 607–610 CrossrefGoogle Scholar

  • [13] Werness P., Brown CM., Smith LH., Finlayson B., EQUIL II: a BASIC computer program for the calculation of urinary saturation. J Urol, 1985, 134, 1242–1244 Google Scholar

  • [14] Witten IH., Frank E. Data mining:practical machine learning tools and techniques with Java implementations. Morgan Kaufman: San Francisco, 2000. Google Scholar

  • [15] Milošević D., Batinić D., Konjevoda P., Blau N., Štambuk N., Nižić L.j, et al. of calcium, oxalate, and citrate interaction in idiopathic calcium urolithiasis in children. J Chem Inf Comput Sci, 2003, 43(6), 1844–1847 http://dx.doi.org/10.1021/ci020060jCrossrefGoogle Scholar

  • [16] Chutipongtanate S. and Thongboonkerd V. Ceftriaxone crystallization and it potential role in kidney stone formation. Biochem Biophys Res Commun., 2011 Mar, 406(3), 396–402 http://dx.doi.org/10.1016/j.bbrc.2011.02.053CrossrefGoogle Scholar

  • [17] Reid DG., Jackson GJ., Duer MJ., Rodgers AL. Apatite in kidney stones is a molecular composite with glycosaminogycans and proteins: evidence from nuclear magnetic resonance spectroscopy, and relevance to Randall’s plaque, pathogenesis and prophylaxis. J Urol, 2011 Feb, 185(2), 725–730 http://dx.doi.org/10.1016/j.juro.2010.09.075Web of ScienceCrossrefGoogle Scholar

  • [18] Hesse A. and Heimbach D. Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol, 1999 Oct, 17(5), 308–315 http://dx.doi.org/10.1007/s003450050152CrossrefGoogle Scholar

  • [19] Battino BS., DeFOOR W., Coe F., Tackett L., Erhard M., Wacksman J., Sheldon CA., Minevich E. Metabolic evaluation of children with urolithiasis: arer adult references for supersaturation appropriate?. J Urol, 2002 Dec, 168(6), 2568–2571 http://dx.doi.org/10.1016/S0022-5347(05)64217-6CrossrefGoogle Scholar

  • [20] Patzer L., van’t Hoff W., Shah V., Halson P., Kasidas GP., Colin S., de Bruyn R., Baratt TM., Dillon MJ. Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy school children. J Pediatr, 1999 Nov, 135(5), 611–617 http://dx.doi.org/10.1016/S0022-3476(99)70060-0CrossrefGoogle Scholar

  • [21] Shiffman M., Keith FB., Moore EW. Pathogenesis of seftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology, 1990 Dec, 99(6), 1772–1776 Google Scholar

  • [22] Malsy A. and Bohner M. Brushite conversion into apatite. European Cells and Minerals Vol, 10. Suppl. 1, 2005, (page 28) Google Scholar

  • [23] Asplin J., Parks J., Lingeman J., Kahnoski R., Mardis H., Lacey S., Goldfarb D., Grasso M., Coe F. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol, 1998 Jun, 159(6), 1821–1825 http://dx.doi.org/10.1016/S0022-5347(01)63164-1CrossrefGoogle Scholar

About the article

Published Online: 2013-04-17

Published in Print: 2013-06-01


Citation Information: Open Medicine, Volume 8, Issue 3, Pages 354–357, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-012-0091-z.

Export Citation

© 2013 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Reactions Weekly, 2013, Volume 1458, Number 1, Page 14

Comments (0)

Please log in or register to comment.
Log in